Cartesian Therapeutics (RNAC) EBT Margin (2015 - 2026)
Cartesian Therapeutics (RNAC) reported EBT Margin of 32657.69% for Q1 2026, down 3085097.0% year-over-year from N/an in Q1 2025, and down 712.03% quarter-over-quarter from 5335.93% in Q4 2025.
Cartesian Therapeutics (RNAC) EBT Margin (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of EBT Margin data on file, last reported at 32657.69% in Q1 2026.
- EBT Margin for Q1 2026 came in at 32657.69%, down 3085097.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 15480.98% (up 1561347.0% YoY), and the FY2025 annual result was 34873.75%, down 3467222.0% from the prior year.
- EBT Margin fell to 32657.69% in Q1 2026 per RNAC's latest filing, from 5335.93% in the prior quarter.
- Over five years, EBT Margin peaked at 5335.93% in Q4 2025 and troughed at 32657.69% in Q1 2026.
- A 5-year average of 2428.24% and a median of 173.02% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2026: EBT Margin jumped 411691 bps in 2024, then tumbled 3085097 bps in 2026.
- A 5-year view of EBT Margin shows it stood at 33.37% in 2022, then tumbled by 7229 bps to 2379.12% in 2023, then jumped by 173 bps to 1737.8% in 2024, then surged by 207 bps to 5335.93% in 2025, then tumbled by 712 bps to 32657.69% in 2026.
- Business Quant data shows RNAC's EBT Margin at 32657.69% in Q1 2026, 5335.93% in Q4 2025, and 4318.14% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | -32,657.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32,657.69% |
| Dec 31, 2025 | 5,335.93% |
| Sep 30, 2025 | -4,318.14% |
| Mar 31, 2025 | -1,806.73% |
| Dec 31, 2024 | 1,737.80% |
| Sep 30, 2024 | -3,876.49% |
| Jun 30, 2024 | 44.94% |
| Mar 31, 2024 | -208.63% |
| Dec 31, 2023 | -2,379.12% |
| Sep 30, 2023 | -137.41% |
| Jun 30, 2023 | -342.85% |
| Mar 31, 2023 | -300.74% |
| Dec 31, 2022 | 33.37% |
| Sep 30, 2022 | -39.66% |
| Jun 30, 2022 | 34.00% |
| Mar 31, 2022 | 29.65% |
| Dec 31, 2021 | 41.34% |
| Sep 30, 2021 | -8.46% |
| Jun 30, 2021 | -1.26% |
| Mar 31, 2021 | -71.10% |